This announcement is a separate document:
百诚医药：关于2023HY252获得临床试验批准通知书的公告
Baicheng Pharmaceutical: Announcement on 2023HY252 Obtaining Clinical Trial Approval Notice
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.